Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...
Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...
Nxera Pharma Co., Ltd. announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGlu...
ICP DAS-BMP (Biomedical Polymers), a committed Taiwan-based manufacturer and supplier of medical-grade TPU (thermoplastic polyurethane), is excited to...
Actinium Pharmaceuticals, Inc.(Actinium or the Company), a pioneer in the development of targeted radiotherapies, announced it has entered into an agreemen...
Clover Biopharmaceuticals, Ltd, a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and ...
CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...
Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
AstraZeneca announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre together with major research and manu...
Terumo Neuro, a global leader in neurovascular innovation and a wholly-owned subsidiary of Terumo Corporation, proudly celebrates the 15th anniversary of t...
Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned s...
Paratek Pharmaceuticals and Optinose, Inc. announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, includ...
Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleas...
TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regime...
© 2025 Biopharma Boardroom. All Rights Reserved.
